Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 5,000 Shares

Glaukos Co. (NYSE:GKOSGet Free Report) Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $112.00, for a total transaction of $560,000.00. Following the sale, the director now owns 30,620 shares of the company’s stock, valued at $3,429,440. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Stock Up 1.4 %

GKOS stock opened at $114.29 on Tuesday. The stock has a market capitalization of $5.76 billion, a P/E ratio of -39.68 and a beta of 1.09. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. Glaukos Co. has a one year low of $59.22 and a one year high of $115.61. The company has a 50 day moving average price of $101.91 and a two-hundred day moving average price of $89.20.

Glaukos (NYSE:GKOSGet Free Report) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The firm had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The firm’s revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.59) earnings per share. As a group, sell-side analysts expect that Glaukos Co. will post -2.26 EPS for the current year.

Institutional Trading of Glaukos

Several institutional investors have recently made changes to their positions in GKOS. National Bank of Canada FI purchased a new stake in shares of Glaukos during the 4th quarter valued at $46,000. GAMMA Investing LLC purchased a new stake in shares of Glaukos during the 4th quarter valued at $55,000. Quadrant Capital Group LLC grew its stake in shares of Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 329 shares during the period. Caldwell Sutter Capital Inc. boosted its position in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares during the period. Finally, Cetera Advisors LLC purchased a new stake in Glaukos during the 1st quarter worth $213,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Stifel Nicolaus restated a “buy” rating and set a $110.00 price objective on shares of Glaukos in a research report on Wednesday, April 3rd. Mizuho lifted their price objective on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Truist Financial restated a “buy” rating and set a $125.00 price objective (up from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. Finally, BTIG Research lifted their price objective on Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.45.

Read Our Latest Research Report on Glaukos

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Further Reading

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.